Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avalo Therapeutics Inc

Healthcare US AVTX

17.83USD
0.75(4.39%)

Last update at 2026-06-23T20:04:00Z

Day Range

16.7118.54
LowHigh

52 Week Range

3.3920.72
LowHigh

Fundamentals

  • Previous Close 17.08
  • Market Cap334.08M
  • Volume1968138
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-72.58100M
  • Revenue TTM0.06M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -35.28700M
  • Diluted EPS TTM-5.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -78.09400M -35.01500M -31.53000M -41.63000M -84.54500M
Minority interest - - - - -
Net income -78.25900M -35.12900M -31.54400M -41.65800M -84.34900M
Selling general administrative 22.43M 16.45M 10.27M 20.64M 21.83M
Selling and marketing expenses 0.47M 0.79M 0.03M 0.08M 2.83M
Gross profit -0.28500M 0.81M 0.64M 14.62M 3.91M
Reconciled depreciation 0.34M 0.17M 0.15M 0.17M 1.66M
Ebit -73.26900M -68.51200M -23.44400M -37.44000M -82.13400M
Ebitda -72.92500M -68.34300M -23.28600M -37.42200M -80.58600M
Depreciation and amortization 0.34M 0.17M 0.16M 0.02M 1.55M
Non operating income net other - - - - -
Operating income -72.92500M -68.51200M -27.35100M -37.44000M -82.13400M
Other operating expenses 72.98M 68.95M 29.27M 55.49M 87.53M
Interest expense - 3.32M 3.42M 4.17M 2.39M
Tax provision 0.17M 0.11M 0.03M 0.03M -0.19600M
Interest income - - - - -
Net interest income 4.35M 3.32M -4.44700M -4.17000M -2.39100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.17M 0.11M 0.01M 0.03M -0.19600M
Total revenue 0.06M 0.44M 1.92M 18.05M 5.40M
Total operating expenses 72.98M 69.32M 27.99M 52.06M 86.04M
Cost of revenue 0.34M -0.36600M 1.28M 3.43M 1.49M
Total other income expense net -5.16900M 33.50M -4.17900M -4.19000M -2.41100M
Discontinued operations - - - - -0.02700M
Net income from continuing ops -78.25900M -35.12900M -33.18800M -41.65800M -84.34900M
Net income applicable to common shares - - - - -84.37600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 116.46M 150.73M 20.99M 33.37M 80.21M
Intangible assets - - - - 0.04M
Earning assets - - - - -
Other current assets 6.95M 3.73M 0.84M 1.29M 2.37M
Total liab 33.41M 17.70M 13.69M 44.28M 57.13M
Total stockholder equity 83.05M 133.03M 7.30M -10.91500M 23.08M
Deferred long term liab - - - - -
Other current liab 12.41M 6.11M 3.63M 13.21M 0.00900M
Common stock 0.02M 0.01000M 0.00100M 0.00900M 0.11M
Capital stock 0.02M 0.01000M 0.00100M 0.00900M 0.11M
Retained earnings -448.52200M -370.26300M -335.13400M -303.82400M -262.16600M
Other liab - - - 6.97M 4.41M
Good will 10.50M 10.50M 10.50M 14.41M 14.41M
Other assets - - 0.00000M - 1.23M
Cash 15.86M 134.55M 7.42M 13.17M 54.59M
Cash and equivalents - - - - -
Total current liabilities 12.94M 6.96M 4.62M 22.11M 19.89M
Current deferred revenue - - - 0.09M 16.02M
Net debt -13.43100M -133.97800M -3.51300M 6.24M -21.75200M
Short term debt 0.39M 0.57M 0.54M 5.93M 0.48M
Short long term debt - - - 5.93M -
Short long term debt total 2.43M 0.57M 3.90M 19.42M 32.83M
Other stockholder equity 531.49M 503.29M 342.44M 292.90M 285.13M
Property plant equipment - - - 2.41M 2.69M
Total current assets 105.29M 138.89M 8.39M 16.42M 61.84M
Long term investments - - - - -
Net tangible assets - - - -25.32400M 8.63M
Short term investments 82.48M 0.00000M - - -
Net receivables - 0.61M 0.14M 1.92M 4.80M
Long term debt - - - 13.49M 32.83M
Inventory - - 0.00000M 0.02M 0.04M
Accounts payable 0.14M 0.28M 0.45M 2.88M 3.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.07M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.21M 0.13M 0.13M 0.13M 1.23M
Deferred long term asset charges - - - - -
Non current assets total 11.17M 11.84M 12.60M 16.95M 18.37M
Capital lease obligations 0.39M 0.57M 0.54M 0.53M 0.48M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -81.72000M 0.36M -0.13300M -0.09500M -0.11300M
Change to liabilities - - - 0.00000M 0.80M
Total cashflows from investing activities -81.72000M 0.36M -0.13300M -0.09500M -0.11300M
Net borrowings - 0.00000M -21.24400M -14.80600M 32.90M
Total cash from financing activities 14.59M 175.85M 25.04M -14.69900M 106.76M
Change to operating activities - - - 4.09M 0.96M
Net income -78.25900M -35.12900M -31.54400M -41.65800M -84.37600M
Change in cash -118.59100M 127.15M -5.77100M -41.54500M 35.76M
Begin period cash flow 134.70M 7.55M 13.32M 54.86M 19.11M
End period cash flow 16.11M 134.70M 7.55M 13.32M 54.86M
Total cash from operating activities -51.45800M -49.05600M -30.68000M -26.75100M -70.89200M
Issuance of capital stock 14.76M 115.62M 46.25M 0.03M 71.93M
Depreciation 0.34M 0.17M 0.16M 0.17M 1.66M
Other cashflows from investing activities 0.69M 0.36M 0.03M - -
Dividends paid - - - 14.81M -
Change to inventory - 0.00000M 0.02M 0.02M -0.03500M
Change to account receivables - -0.47500M 1.78M 1.06M 1.12M
Sale purchase of stock 0.02M 0.07M 0.07M 0.07M 0.37M
Other cashflows from financing activities -0.51000M 60.22M 0.07M 14.81M 34.47M
Change to netincome - - - - 8.19M
Capital expenditures 0.00000M 0.00000M 0.16M 0.10M 0.11M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.84M -4.70800M -9.24000M 4.77M 2.84M
Stock based compensation 13.62M 5.85M 3.48M 7.55M 8.17M
Other non cash items 8.83M -15.35400M 6.46M 2.39M 0.79M
Free cash flow -51.45800M -49.05600M -30.83800M -26.84600M -71.00500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVTX
Avalo Therapeutics Inc		 0.75 4.39% 17.83 - - 5662.35 4.02 4002.28 -0.1887
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Avalo Therapeutics Inc

1500 Liberty Ridge Drive, Wayne, PA, United States, 19087

Key Executives

Name Title Year Born
Dr. Garry A. Neil M.D. Chairman, Pres & CEO 1954
Dr. Solomon H. Snyder M.D. Founder and Chairman of Scientific Advisory Board 1939
Dr. Barbara S. Slusher Ph.D. Founder and Member of Scientific Advisory Board 1965
Mr. Christopher Ryan Sullivan Chief Financial Officer 1985
Dr. Lisa Hegg Ph.D. Sr. VP of Program Management & Corp. Infrastructure NA
Mr. Maxim Jacobs C.F.A. VP of Investor Relations NA
Dr. Stephen Thomas Ph.D. VP & Head of Discovery NA
Ms. Colleen Matkowski Sr. VP of Global Regulatory Affairs & Quality Assurance NA
Dr. Dino C. Miano Ph.D. Sr. VP of CMC & Technical Operations NA
Dr. Blake M. Paterson M.D. Scientific Advisor 1957

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.